Overview
- Species: Human
- Features: cryopreserved, male, TARGATT
- Product Type: TARGATT Kits
- iPSC: iPSC control line, iPSC Services
- Packaging:Kit consists of AST-9650-C, AST-3091, and AST-3084
ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit
Cat.-Nr.: AST-9450
Description
Accelerate development of engineered iPSC-derived cell products with a RUO hiPSC line built for site-specific gene insertion using TARGATT™ technology.
- Insert genes with confidence—with TARGATT™ technology you can achieve site-specific, single-copy, insertion of up to 20 kb at the reliable H11 safe-harbor locus
- Build complex constructs—up to 20 kb knock-in capabilities mean you can engineer and evaluate large therapeutic payloads, synthetic circuits, or immune-modifying elements
- Develop efficiently—rapidly iterate on genome editing strategies before transitioning to the isogenic GMP line. Contact us for more information.
- Streamline commercialization—straightforward licensing with clear freedom-to-operate
The ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit gives you a powerful foundation for building engineered iPSC-derived cell products with high precision and biological relevance. Derived from neonatal CD34+ cord blood cells, these hiPSCs start with a lower mutational burden and broader developmental potential than adult somatic sources, making them a superior starting point for applications that require genomic stability and flexible lineage differentiation.
Pre-engineered with a TARGATT™ landing pad at the H11 safe harbor locus, the ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit enables site-specific, single-copy insertion of large DNA payloads—up to 20 kb (more with nested reactions)—with consistent and predictable expression. This targeted integration eliminates the variability, silencing, and safety concerns associated with random integration methods.
If you need a customized version of this line we offer full iPSC gene editing services to meet your specific needs.
The parental hiPSC line used for AST-9450 has been successfully differentiated into cardiomyocytes, natural killer (NK) cells, T cells, monocytes/macrophages, and endothelial cells—demonstrating its versatility across a range of lineages.
Each ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit contains sufficient cells and plasmids for 3 transfections and comes with:
– ActiCells™ RUO TARGATT™ hiPSC Master Cell Line (Cat.# AST-9450-C)
– TARGATT™ 46 CAG-MCS Cloning Plasmid (Cat.# AST-3091)
– TARGATT™ CAG-Integrase Plasmid (Cat.# AST-3084)
As with all TARGATT™ technology-enabled products, this kit requires a license for commercial use and a materials transfer agreement (MTA) for academic use.
Contact us for more information!
SUPPLIER:
Applied StemCell
STATUS:
In Stock
SIZE:
kit
ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit
Related Files
FAQs
Can I use the ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit for clinical applications?
No, the ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in Kit is for research use only. Please contact us to discuss whether the ActiCells™ GMP TARGATT™ hiPSC Knock-in Kit, the corresponding GMP-grade kit for clinical applications, might be a suitable option.
How was the ActiCells™ RUO TARGATT™ hiPSC Master Cell Line created?
The ActiCells™ RUO TARGATT™ iPSC Master Cell Line is engineered from our ActiCells™ GMP hiPSC Line, a well-characterized, karyotype-normal hiPSC line reprogrammed from CD34+ cord blood cells from a fully consented male donor.
How does TARGATT™ technology compare to other gene insertion methods?
TARGATT™ technology enables highly efficient, single-copy, site-specific integration at the H11 safe harbor locus. Integration is stable and results in long-term expression—advantages that other random or multi-copy insertion methods cannot consistently provide.
What is the knock-in efficiency of TARGATT™ technology?
TARGATT™ technology provides high knock-in efficiency with stable and site-specific gene integration. After drug selection, efficiency can approach 90%.
How does TARGATT™ ensure minimal off-target effects?
The TARGATT™ system uses a patented serine integrase that specifically recognizes TARGATT™ attB sites in the cloning plasmid (also referred to as the donor plasmid) and attP sites in the TARGATT landing pad. Because unbound double strand breaks are not created, random integration using the host double strand break repair machinery does not occur.
What is the cargo size capacity of TARGATT™ technology?
TARGATT™ can efficiently insert payloads of 20 kb in a single reaction and larger payloads with nested TARGATT™ landing pads, making the technology suitable for a wide range of genetic engineering applications.
Can I customize the gene of interest for knock-in using TARGATT™?
Yes, the TARGATT™ cloning plasmid allows you to clone and amplify your desired gene of interest for site-specific insertion.
hiEX™ Research iPSC Exosomes